Erdafitinib extends survival in post-immunotherapy, FGFR-altered urothelial cancer
Findings form the phase 3 THOR trial (NCT03390504) presented during the 2023 ASCO Annual Meeting showed that erdafitinib (Balversa) significantly improved overall survival compared with investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who had previously received an anti–PD-(L)1 therapy.Source: Urology Times
Various Cancer Treatment Drugs Experiencing Nationwide Shortage
Dr. Daniel Petrylak, chief of genitourinary oncology at Yale Cancer Center, said some patients have had to switch between certain cancer-treating drugs while waiting for a new supply to come in. “We’re making every effort to give our patients the best possible care, but we hope in the future that this is not going to be more of a magnified problem. We have to start thinking and planning ahead as to how we can alleviate this drug crisis," Petrylak said.Source: NBC 30
'Young and the Restless' star Eric Braeden talks bladder cancer. What to know about symptoms, causes
Veteran "Young and the Restless" actor Eric Braeden recently disclosed he has bladder cancer and detailed his diagnosis and immunotherapy treatment. The important thing to remember: "There's hope," says Dr. Daniel Petrylak, chief of genitourinary oncology at Yale Cancer Center and Smilow Cancer Hospital.Source: USA Today
Yale Urology Research [Q1: January-March 2023]
View this comprehensive list of Yale Urology faculty publications for the 1st quarter of calendar year 2023. The listing is separated into primary and secondary faculty sections, then in descending published date order. Most references include cite details and portions of each abstract/summary.